Add to your
favorites

Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1)

for PXL065, a Novel, Proprietary Deuterium-Stabilized Rstereoisomer of Pioglitazone

Press release

PXL065 Phase 2 trial for the treatment of NASH met its primary efficacy endpoint for liver fat content reduction at 36-weeks for all doses.
Histology findings from paired liver biopsies showed strong improvement in fibrosis without worsening of NASH, consistent with dose dependent reduction of all biomarkers related to fibrogenesis and fibrosis risk scores; improvement seen in other NASH histology components.
Additional benefits on glucose control (HbA1c) and multiple indices of insulin sensitivity.
Validation of PXL065 hypothesis – combining efficacy on liver and metabolic endpoints with reduced potential for PPARγ side effects (weight gain and edema).
Investor webcast today to further discuss data